Main > A1. CORP. INDEX. A-Am No. 1 > Aeterna Zentaris Inc./P C2

---

This data is not available for free

Aeterna Zentaris Inc./P C2's subsections
2007. 12.03.2007. Corp. Sale
2010. 06.07.2010. Onco.>AEZS-108>Ov
2010. 06.28.2010. Onco.>AEZS-108
2010. 07.14.2010. Onco.>Perifosine
2011. 03.15.2011. Onco.>AEZS-129
2011. 07.20.2011. Onco.>AEZS-120
2011. 08.31.2011. Onco.>Perifosine
2011. 10.05.2011. Onco.>Perifosine
2011. 10.25.2011. Onco.>AEZS-108>Br
2011. 11.23.2011. Hikma Pharma.
2011. 12.09.2011. Onco.>AEZS-131
2011. 12.13.2011. Onco.>Perifosine
2012. 01.03.2012. Yakult Honsha
2012. 01.05.2012. Ventana Medical
2012. 02.03.2012. Onco.>AEZS-108>Pr
2012. 03.08.2012. Onco.>AEZS-130
2012. 09.25.2012. Endo.>AEZS-130
2012. 12.28.2012. Onco.>AEZS-108>En
2013. 03.11.2013. Onco.>Perifosine
2013. 04.17.2013. Merck KGaA
2014. 06.10. Specialty Biopharma Co
2017. 12.20. USA Approval
2019. 01.16. EU Clearance
2020. 06.25. IL>Licensee
2020. 12.07. EU>Licensee
2022. 03.02. USA Patent
2022. 04.19. Endo.>GHD>Diag>EU Pate
2023. 12.14. Ceapro Merger
Web-Site

Aeterna Zentaris Inc./P C2's products
This section has no products